AzTrials
AzTrials

Type 2 Diabetes MellitusPhase 3SURPASS-CVOTNCT04255433

A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

A Phase 3 study testing Tirzepatide and Dulaglutide in people with Type 2 Diabetes Mellitus, run by Eli Lilly and Company at 635 sites in 31 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk. Read more about this study

Who is it for?
Ages 40 years and older
Conditions the study is for
Type 2 Diabetes Mellitus
What is being tested?
Tirzepatide and Dulaglutide
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
13,299 participants
Where
635 sitesin 31 countries
Study dates
29 May 2020to 12 Jun 2025
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 40 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men or women at least 40 years old with a diagnosis of type 2 diabetes
  • Established cardiovascular disease, including at least 1 of the following:
  • Coronary artery disease (CAD) with any of the following:
  • Documented history of spontaneous myocardial infarction (MI)
  • ≥50% stenosis in 1 or more major coronary arteries, determined by invasive angiography
  • ≥50% stenosis in 2 or more major coronary arteries, determined by computed tomography coronary angiography (CTCA)
Show all 34Show fewer
  • History of surgical or percutaneous coronary revascularization procedure
  • Cerebrovascular disease - any of the following:
  • Documented history of ischemic stroke
  • Carotid arterial disease with ≥50% stenosis, documented by carotid ultrasound, magnetic resonance imaging (MRI), or angiography
  • Carotid stenting or surgical revascularization
  • Peripheral arterial disease with either of the following:
  • Intermittent claudication and ankle-brachial index <0.9
  • Prior nontraumatic amputation or peripheral vascular procedure (eg, stenting or surgical revascularization), due to peripheral arterial ischemia
  • Note: Supporting medical documentation is required in all instances
  • HbA1c ≥7% (≥53 mmol/mol) and ≤10.5% (≤91.3 mmol/mol) based on central laboratory assessment at screening
  • Body mass index (BMI) ≥25 kg/m2
  • At the time of signing the informed consent: Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical trials.
  • Male patients: Men, regardless of their fertility status, with nonpregnant women of childbearing potential (WOCBP) partners must agree to either remain abstinent (if this is their preferred and usual lifestyle) or use condoms, as well as 1 additional highly effective (less than 1% failure rate) method of contraception (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) or effective method of contraception (such as diaphragms with spermicide or cervical sponges) for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug.
  • Men and their partners may choose to use a double-barrier method of contraception. (Barrier protection methods without concomitant use of a spermicide are not an effective or acceptable method of contraception. Thus, each barrier method must include use of a spermicide. It should be noted, however, that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these barrier methods are combined).
  • Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception.
  • Men with pregnant partners should use condoms during intercourse for the duration of the study and until the end of the estimated relevant potential exposure in WOCBP (90 days). Men should refrain from sperm donation for the duration of the study and until their plasma concentrations are below the level that could result in a relevant potential exposure to a possible fetus, predicted to be 90 days following the last dose of study drug. Men who are in exclusively same-sex relationships (as their preferred and usual lifestyle) are not required to use contraception.
  • Female patients: Women of childbearing potential who are abstinent (if this is complete abstinence, as their preferred and usual lifestyle) or in a same-sex relationship (as part of their preferred and usual lifestyle) must agree to either remain abstinent or stay in a same-sex relationship without sexual relationships with males. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation methods), declaration of abstinence just for the duration of a trial, and withdrawal are not acceptable methods of contraception. Otherwise, WOCBP participating must agree to use 2 forms of effective contraception, where at least 1 form is highly effective (less than 1% failure rate), for the entirety of the study. Contraception must continue following completion of study drug administration for the entirety of the study and for 30 days thereafter.
  • WOCBP participating must test negative for pregnancy prior to initiation of treatment as indicated by a negative serum pregnancy test at the screening visit followed by a negative urine pregnancy test within 24 hours prior to exposure.
  • Two forms of effective contraception, where at least 1 form is highly effective, (such as combination oral contraceptives, implanted contraceptives, or intrauterine devices) will be used. Effective contraception (such as male or female condoms with spermicide, diaphragms with spermicide, or cervical sponges) may be used as the second therapy. Barrier protection methods without concomitant use of a spermicide are not a reliable or acceptable method. Thus, each barrier method must include use of a spermicide (ie, condom with spermicide, diaphragm with spermicide, or female condom with spermicide). It should be noted that the use of male and female condoms as a double barrier method is not considered acceptable due to the high failure rate when these methods are combined.
  • Women not of childbearing potential may participate and include those who are:
  • infertile due to surgical sterilization (hysterectomy, bilateral oophorectomy, or tubal ligation), congenital anomaly such as mullerian agenesis, or
  • postmenopausal - defined as either: A woman at least 40 years of age with an intact uterus, not on hormone therapy, who has cessation of menses for at least 1 year without an alternative medical cause, AND a follicle-stimulating hormone >40 mIU/mL; or ii. A woman 55 or older not on hormone therapy, who has had at least 12 months of spontaneous amenorrhea; or A woman at least 55 years of age with a diagnosis of menopause prior to starting hormone replacement therapy.
  • In the investigator's opinion, are well motivated, capable, and willing to:
  • learn how to self-inject treatment (tirzepatide or dulaglutide), as required for this protocol (visually impaired persons who are not able to perform the injections must have the assistance of a sighted individual trained to inject the study drug; persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the study drug),
  • inject study drug weekly,
  • have a sufficient understanding of 1 of the provided languages of the country such that they will be able to complete the patient questionnaires, and
  • make themselves available for the duration of the study, and who will comply with the required study visits.
  • Capable of giving signed informed consent

Who cannot join

  • Have type 1 diabetes mellitus
  • Have uncontrolled diabetes requiring immediate therapy (such as diabetic ketoacidosis) at screening or randomization, in the judgment of the physician
  • Have had 1 or more events of severe hypoglycemia and/or 1 or more events of hypoglycemia unawareness within 6 months prior to screening
  • Are currently planning treatment for diabetic retinopathy and/or macular edema.
  • Have been hospitalized for congestive heart failure (CHF) within 2 months prior to screening
  • Have chronic New York Heart Association Functional Classification IV CHF
Show all 28Show fewer
  • Are currently planning a coronary, carotid, or peripheral artery revascularization
  • Had chronic or acute pancreatitis any time prior to screening, irrespective of etiology
  • Have a known clinically significant gastric emptying abnormality such as severe gastroparesis or gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery
  • Have acute or chronic hepatitis, signs or symptoms of any other liver disease, an alanine aminotransferase (ALT) level ≥3 times the upper limit of normal (ULN) for the reference range, as determined by the central laboratory (Note: Patients with nonalcoholic fatty liver disease are eligible to participate if their ALT level is <3 times the ULN for the reference range)
  • Have known chronic severe renal failure (defined as a known estimated glomerular filtration rate (eGFR) <15 mL/minute/1.73 m2) or are on chronic dialysis
  • Have evidence of a significant, uncontrolled endocrine abnormality (eg, thyrotoxicosis or adrenal crises)
  • Have a family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (MTC) or personal history of nonfamilial MTC
  • Have a serum calcitonin level at screening of: (based on central laboratory results)
  • ≥20 ng/L at Visit 1, if eGFR ≥60 mL/min/1.73 m2, or
  • ≥35 ng/L at Visit 1, if eGFR <60 mL/min/1.73 m2
  • Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years. An exception for this criterion is basal or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer
  • Have a history of any other condition (such as known drug or alcohol abuse or psychiatric disorder) that, in the opinion of the investigator, may preclude the patient from following and completing the protocol
  • Have had a transplanted organ (corneal transplants [keratoplasty] allowed) or awaiting an organ transplant
  • Have any other condition (eg, hypersensitivity) that is a contraindication to any incretin or glucagon-like peptide-1 (GLP-1) receptor agonist (RA)
  • Have had an MI, percutaneous coronary revascularization procedure, ischemic stroke, carotid stenting or surgical revascularization, nontraumatic amputation, or peripheral vascular procedure (eg, stenting or surgical revascularization) less than 60 days prior to screening
  • Have had coronary artery bypass graft surgery less than 5 years prior to screening
  • Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement
  • Treatment with GLP-1 RA or pramlintide, in a period of 3 months prior to Visit 1
  • Discontinuation of GLP-1 RA or pramlintide, due to intolerability any time prior to Visit 1
  • Are currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have participated within the last 30 days in a clinical trial involving an investigational product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
  • Have previously completed or withdrawn from this study or randomized into any other study investigating tirzepatide

Trial locations and contacts

635 sites in 31 countries.

635 sites in 31 countries

United States121 sites

  • Albany Medical College, Division of Community Endocrinology

    Albany, New York, 12203

  • Orlando Heart & Vascular Institute, LLC

    Altamonte Springs, Florida, 32714

  • Northwest Heart Clinical Research

    Arlington Heights, Illinois, 60005

  • Atlanta Diabetes Associates

    Atlanta, Georgia, 30318

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, 80045

  • Ascension Saint Agnes Heart Care

    Baltimore, Maryland, 21229

  • Heritage Valley Medical Group, Inc.

    Beaver, Pennsylvania, 15009

  • Billings Clinic

    Billings, Montana, 59101

  • University of Alabama at Birmingham Medical Center

    Birmingham, Alabama, 35294-0012

  • Elite Clinical Trials

    Blackfoot, Idaho, 83221

  • Excel Medical Clinical Trials

    Boca Raton, Florida, 33434

  • Brigham and Women's Hospital Diabetes Program

    Boston, Massachusetts, 02115

  • Joslin Diabetes Center

    Boston, Massachusetts, 02215

  • Qualmedica Research

    Bowling Green, Kentucky, 42101

  • Holston Medical Group

    Bristol, Tennessee, 37620

  • Mercury Street Medical Group, PLLC

    Butte, Montana, 59701

  • Capital Area Research, LLC

    Camp Hill, Pennsylvania, 17011

  • Ralph H. Johnson VA Medical Center

    Charleston, South Carolina, 29401

  • Atrium Health - Department of Family Medicine Research

    Charlotte, North Carolina, 28207

  • Cedar-Crosse Research Center

    Chicago, Illinois, 60607

  • StudyMetrix Research

    City of Saint Peters, Missouri, 63303

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195

  • John Muir Medical Center - Concord Campus

    Concord, California, 94520

  • Private Practice - Dr. Osvaldo A. Brusco

    Corpus Christi, Texas, 78414

  • Valley Clinical Trials, Inc.

    Covina, California, 91723

  • Dallas Diabetes Research Center

    Dallas, Texas, 75230

  • North Texas Endocrine Center

    Dallas, Texas, 75231

  • Research Institute of Dallas

    Dallas, Texas, 75231

  • Texas Health Physicians Group

    Dallas, Texas, 75231

  • Galenos Research

    Dallas, Texas, 75251

  • Physicians' Research Options

    Draper, Utah, 84020

  • Kaiser Permanente - Dutluth, GA

    Duluth, Georgia, 30096

  • Duke University

    Durham, North Carolina, 27710

  • St. John's Hospital

    Edina, Minnesota, 55435

  • Academy of Diabetes, Thyroid and Endocrine

    El Paso, Texas, 79935

  • AMCR Institute

    Escondido, California, 92025

  • The University of Kansas - Clinical Research Center

    Fairway, Kansas, 66205

  • Virginia Heart

    Falls Church, Virginia, 22042

  • Lillestol Research

    Fargo, North Dakota, 58104

  • Decpa, Llc

    Feasterville, Pennsylvania, 19053

  • Diabetes and Thyroid Center of Ft. Worth

    Fort Worth, Texas, 76132

  • Valley Research

    Fresno, California, 93720

  • NorCal Medical Research, Inc

    Greenbrae, California, 94904

  • Tribe Clinical Research, LLC

    Greenville, South Carolina, 29607

  • Clinical Investigation Specialists

    Gurnee, Illinois, 60031

  • CMR of Greater New Haven, LLC

    Hamden, Connecticut, 06517

  • Encore Medical Research

    Hollywood, Florida, 33024

  • East-West Medical Research Institute

    Honolulu, Hawaii, 96814

  • VA Pacific Islands Health Care System

    Honolulu, Hawaii, 96819

  • Northwest Houston Cardiology - Cypress

    Houston, Texas, 77070

  • MedStar Health Research Institute (MedStar Physician Based Research Network)

    Hyattsville, Maryland, 20782

  • Rocky Mountain Clinical Research

    Idaho Falls, Idaho, 83404

  • University of Iowa

    Iowa City, Iowa, 52242

  • East Coast Institute for Research, LLC

    Jacksonville, Florida, 32204

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida, 32216

  • NSC Research

    Johns Creek, Georgia, 30024

  • Clinical Investigation Specialists

    Kenosha, Wisconsin, 53144

  • PMG Research, Inc. d/b/a PMG Research of Knoxville

    Knoxville, Tennessee, 37938

  • UCSD - Altman Clinical and Translational Research Institute (ACTRI)

    La Jolla, California, 92037

  • First Valley Medical Group

    Lancaster, California, 93534

  • Accel Research Sites - St. Pete-Largo Clinical Research Unit

    Largo, Florida, 33777

  • Palm Research Center Tenaya

    Las Vegas, Nevada, 89128

  • Palm Research Center Sunset

    Las Vegas, Nevada, 89148

  • Physicians Research Associates

    Lawrenceville, Georgia, 30045

  • L-MARC Research Center

    Louisville, Kentucky, 40213

  • East Coast Institute for Research at The Jones Center

    Macon, Georgia, 31210

  • M Health Fairview St. John's Hospital

    Maplewood, Minnesota, 55109

  • Endocrine Clinic

    Memphis, Tennessee, 38119

  • Southern Endocrinology Associates

    Mesquite, Texas, 75149

  • ActivMed Practices and Research

    Methuen, Massachusetts, 01844

  • Monterey Endocrine & Diabetes Institute, Inc.

    Monterey, California, 93940

  • PMG Research Inc., d/b/a PMG of Piedmont Healthcare

    Mooresville, North Carolina, 28117

  • Riverside University Health System - Medical Center

    Moreno Valley, California, 92555

  • Accellacare - Mt Pleasant

    Mt. Pleasant, South Carolina, 29464

  • Southern Nh Diabetes and Endocrinology

    Nashua, New Hampshire, 03060

  • Alliance for Multispecialty Research, LLC

    Norman, Oklahoma, 73069

  • Infinity Medical Research

    North Dartmouth, Massachusetts, 02747

  • North Hills Family Medicine/North Hills Medical Research

    North Richland Hills, Texas, 76180

  • Ocala Caridovascular Research

    Ocala, Florida, 34474

  • Advanced Research Institute

    Ogden, Utah, 84405

  • VA Nebraska-Western Iowa Health Care System

    Omaha, Nebraska, 68105

  • University Of Nebraska Medical Center

    Omaha, Nebraska, 68198-4130

  • Diabetes Associates Medical Group

    Orange, California, 92868

  • Qualmedica Research, LLC

    Owensboro, Kentucky, 42301

  • MD Medical Research

    Oxon Hill, Maryland, 20745

  • Cardiology Partners Clinical Research Institute - Palm Beach Gardens

    Palm Beach Gardens, Florida, 33410

  • Pasadena Clinical Research

    Pasadena, California, 91105

  • Thomas Jefferson University - Clinical Research Institute

    Philadelphia, Pennsylvania, 19107

  • Northeast Endocrine Metabolic Associates

    Philadelphia, Pennsylvania, 19114

  • Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)

    Pittsburgh, Pennsylvania, 15236

  • Peace River Cardiovascular Center

    Port Charlotte, Florida, 33952

  • MultiCare Good Samaritan Hospital

    Puyallup, Washington, 98372

  • Monument Health Rapid City Hospital

    Rapid City, South Dakota, 57701

  • Endocrine and Metabolic Consultants

    Rockville, Maryland, 20852

  • CentraCare Heart & Vascular Center

    Saint Cloud, Minnesota, 56303

  • Alpine Medical Group

    Salt Lake City, Utah, 84102

  • Audie L Murphy VA Hospital

    San Antonio, Texas, 75231

  • LCGK Research

    San Carlos, California, 94070

  • Norcal Endocrinology & Internal Medicine

    San Ramon, California, 94583

  • VA Puget Sound Health Care System

    Seattle, Washington, 98108

  • Consano Clinical Research, LLC

    Shavano Park, Texas, 78231

  • Multicare Institute for Research and Innovation

    Spokane, Washington, 99202

  • Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative

    Springfield, Illinois, 62711

  • Clinvest Research LLC

    Springfield, Missouri, 65807

  • Mercy Research - Smith Glynn Callaway

    Springfield, Missouri, 65807

  • Professional Health Care of Pinellas

    St. Petersburg, Florida, 33713

  • Northwest Houston Heart Center

    Tomball, Texas, 77375

  • Cotton O'Neil Diabetes & Endocrinology

    Topeka, Kansas, 66606

  • Cotton O'Neil Mulvane

    Topeka, Kansas, 66606

  • Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

    Torrance, California, 90502

  • Arcturus Healthcare , PLC, Troy Internal Medicine Research Division

    Troy, Michigan, 48098

  • Atlanta Heart Specialists

    Tucker, Georgia, 30084

  • Chase Medical Research, LLC

    Waterbury, Connecticut, 06708

  • Cardiology Partners Clinical Research Institute - Wellington

    Wellington, Florida, 33449

  • Central Washington Health Services Association d/b/a Confluence Health

    Wenatchee, Washington, 98801

  • Iowa Diabetes and Endocrinology Research Center

    West Des Moines, Iowa, 50266

  • Kalo Clinical Research

    West Valley City, Utah, 84120

  • Great Lakes Medical Research, LLC

    Westfield, New York, 14787

  • Accellacare - Wilmington

    Wilmington, North Carolina, 24801

  • Clinical Research of Central Florida

    Winter Haven, Florida, 33880

  • Cardiology Consultants of Philadelphia Yardley

    Yardley, Pennsylvania, 19067

Other trials in United States

Germany47 sites

  • Herz - und Diabeteszentrum Nordrhein - Westfalen, Bad Oeynhausen

    Bad Oeynhausen, North Rhine-Westphalia, 32545

  • CIMS Studienzentrum Bamberg

    Bamberg, Bavaria, 96049

  • Institut für klinische Forschung und Entwicklung

    Berlin, 10437

  • Diabetespraxis Prenzlauer Alle

    Berlin, 13187

  • Diabetes- und Stoffwechselpraxis Bochum

    Bochum, North Rhine-Westphalia, 44869

  • Gemeinschaftspraxis Dres. Jung

    Deggingen, Baden-Wurttemberg, 73326

  • Private Practice - Dr. Claus Busch, Dr. Christian Busch & Dr. Christopher Cramer

    Dortmund, North Rhine-Westphalia, 44137

  • Hausärztlich-Kardiologisches MVZ am Felsenkeller GmbH/Zentrum für klinische Studien

    Dresden, Saxony, 1277

  • Universitaetsklinikum Carl Gustav Carus Dresden

    Dresden, Saxony, 1307

  • Gemeinschaftspraxis für Diabetologie

    Eisenach, Thuringia, 99817

  • ZKS Suedbrandenburg

    Elsterwerda, Brandenburg, 04910

  • InnoDiab Forschung Gmbh

    Essen, North Rhine-Westphalia, 45136

  • Medizentrum Essen Borbeck

    Essen, North Rhine-Westphalia, 45355

  • Private Practice - Dr. Bernd Becker

    Essen, North Rhine-Westphalia, 45355

  • ZKS Dr. Lüdemann

    Falkensee, Brandenburg, 14612

  • ClinPhenomics GmbH & Co KG

    Frankfurt am Main, Hesse, 60596

  • Practice Dr.med. Denger and Dr.med. Pfitzner

    Friedrichsthal, Saarland, 66299

  • MVZ im Altstadt-Carree Fulda GmbH

    Fulda, Hesse, 36037

  • Diabetes Zentrum Dr. Tews

    Gelnhausen, Hesse, 63571

  • Diabetologische Schwerpunktpraxis Harburg

    Hamburg, 21073

  • Diabetes Zentrum Wilhelmsburg

    Hamburg, 21109

  • Diabeteszentrum Hamburg West

    Hamburg, 22607

  • St. Josefskrankenhaus Heidelberg

    Heidelberg, 69115

  • Hausarzt- und Diabetologische Schwerpunktpraxis Hohenmölsen - Weiβenfels

    Hohenmölsen, Saxony-Anhalt, 06679

  • Velocity Clinical Research Leipzig GmbH

    Leipzig, Saxony, 04177

  • Gemeinschaftspraxis Dr. Taeschner/Dr. Bonigut

    Leipzig, Saxony, 04249

  • AmBeNet GmbH

    Leipzig, Saxony, 4107

  • Private Practice - Dr. Ilka Simon-Wagner

    Lichtenfels, Bavaria, 96215

  • Universität zu Lübeck - Institut für Endokrinologie und Diabetes

    Lübeck, Schleswig-Holstein, 23562

  • Diabetologikum Ludwigshafen/Die Praxis am Ludwigsplatz

    Ludwigshafen am Rhein, Rhineland-Palatinate, 67059

  • Praxis Oedeme

    Lüneburg, Lower Saxony, 21339

  • SMO.MD GmbH

    Magdeburg, Saxony-Anhalt, 39120

  • CDG Studienambulanz Hartard

    München, Bavaria, 80809

  • Institut für Diabetesforschung GmbH Münster

    Münster, North Rhine-Westphalia, 48145

  • RED-Institut GmbH

    Oldenburg in Holstein, Schleswig-Holstein, 23758

  • Private Practice - Dr. Christine Kosch

    Pirna, Saxony, 1796

  • Diabetologische Schwerpunktpraxis Marck Linn Pickel

    Pohlheim, Hesse, 35415

  • Praxis Dr. Veronika Wenzl-Bauer

    Rehlingen, Lower Saxony, 66780

  • Private Practice - Dr. Joachim Weimer

    Reinfeld, Schleswig-Holstein, 23858

  • MVZ Riesa am Klinikum Döbeln GmbH

    Riesa, Saxony, 1589

  • Zentrum für klinische Studien

    Saint Ingbert, Saarland, 66386

  • Medizinisches Versorgungszentrum am Bahnhof Spandau

    Spandau, State of Berlin, 13597

  • Diabetologische Schwerpunktpraxis Diabetologikum Speyer

    Speyer, Rhineland-Palatinate, 67346

  • Marienhospital Stuttgart

    Stuttgart, Baden-Wurttemberg, 70199

  • Gemeinschaftspraxis Prof. Dr. med. Stephan Jacob, Dr. med. Frohmut Jacob

    Villingen-Schwenningen, Baden-Wurttemberg, 78048

  • Praxis Sauter & Sauter & Vorbach

    Wangen, Baden-Wurttemberg, 88239

  • Praxis für Inner Medizin - Diabetologische Schwerpunktpraxis

    Zwenkau, Saxony, 04442

Other trials in Germany

Argentina31 sites

  • Instituto de Investigaciones Clínicas Bahia Blanca

    Bahía Blanca, Buenos Aires, 8000

  • Centro Médico Viamonte

    Buenos Aires, Buenos Aires F.D., C1120AAC

  • Mautalen Salud e Investigación

    Buenos Aires, Buenos Aires F.D., C1128AAF

  • Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada

    Buenos Aires, Buenos Aires F.D., C1425AGC

  • CEMEDIC

    Buenos Aires, 1407

  • Glenny Corp

    Buenos Aires, 1430

  • CIPREC

    Buenos Aires, C1061

  • Asociación de Beneficencia Hospital Sirio Libanés

    Buenos Aires, C1419AHN

  • CEMEDIAB

    C.a.b.a., Buenos Aires F.D., C1205AAO

  • Organizacion Medica de Investigacion

    CABA, Buenos Aires, C1015

  • CEDIC

    CABA, Buenos Aires, C1060ABN

  • Centro Medico Privado CEMAIC

    Capital, Córdoba Province, X5008HHW

  • Stat Research S.A.

    Capital Federal, Buenos Aires, 1023

  • Centro de Investigaciones Metabólicas (CINME)

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1056ABI

  • Centro Medico Privado San Vicente Diabetes

    Córdoba, Córdoba Province, 5006

  • CIDIM-Centro Integral de Diagnostico por Imagenes Marchegiani

    Córdoba, X5000AVE

  • Centro Diabetológico Dr. Waitman

    Córdoba, X5000JJS

  • Centro Universitario de Investigación en Farmacologia Clínic

    Corrientes, 3400

  • Instituto de Cardiología "Juana F. Cabral"

    Corrientes, 3400

  • Instituto de Investigaciones Clínicas Mar del Plata

    Mar del Plata, Buenos Aires, 7600

  • DIM Clínica Privada

    Ramos Mejía, Buenos Aires, 1704

  • Instituto Médico Catamarca IMEC

    Rosario, Santa Fe Province, 2000

  • Instituto Médico Fundación Grupo Colaborativo Rosario Investigación y Prevención Medica

    Rosario, Santa Fe Province, 2000

  • Instituto de Investigaciones Clinicas Rosario

    Rosario, Santa Fe Province, S2000CVD

  • Instituto Médico Alas

    Salta, 4400

  • Centro de Investigaciones Médicas Tucuman

    SAN M. de Tucuman, Tucumán Province, T4000AXL

  • Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L

    San Miguel de Tucumán, Tucumán Province, 4000

  • Investigaciones Clínicas Tucumán

    San Miguel de Tucumán, Tucumán Province, 4000

  • Go Centro Medico San Nicolás

    San Nicolás de los Arroyos, Buenos Aires, 2900

  • Sanatorio Norte

    Santiago del Estero, 4200

  • Instituto de Investigaciones Clinicas Zarate

    Zárate, Buenos Aires, B2800DGH

Other trials in Argentina

Canada29 sites

  • LMC Clinical Research Inc. (Barrie)

    Barrie, Ontario, L4N 7L3

  • LMC Diabetes & Endocrinology

    Brampton, Ontario, L6S 0C9

  • Aggarwal and Associates Limited

    Brampton, Ontario, L6T 0G1

  • LMC Diabetes & Endocrinology

    Calgary, Alberta, T2H 2G4

  • Cambridge Cardiac Care Centre

    Cambridge, Ontario, N1R 6V6

  • LMC Clinical Research Inc. (Thornhill)

    Concord, Ontario, L4K 4M2

  • Janik Research Corporation

    Greater Sudbury, Ontario, P3C 1S8

  • Viacar Recherche Clinique

    Greenfield Park, Quebec, J4V 2G8

  • NSHA-QEII Health Sciences Centre-Dickson Bldg

    Halifax, Nova Scotia, B3H 1V7

  • Centre de Recherche Clinique de Laval

    Laval, Quebec, H7T 2P5

  • Manna Research

    Lévis, Quebec, G6W 0M5

  • Milestone Research Inc.

    London, Ontario, N5W 6A2

  • St. Joseph's Health Care

    London, Ontario, N6A 4V2

  • Clinique Sante Cardio MC

    Montreal, Quebec, H1T 3Y7

  • North York Diagnostic and Cardiac Centre

    North York, Ontario, M6B 3H7

  • LMC Clinical Research Inc. (Oakville)

    Oakville, Ontario, L6M 1M1

  • Private Practice - Dr. James Cha

    Oshawa, Ontario, L1G 2K1

  • LMC Manna Research

    Ottawa, Ontario, K2J 0V2

  • Kawartha Cardiology Clinical Trials

    Peterborough, Ontario, K9J 0B2

  • Diex Recherche Quebec

    Québec, G1V 4T3

  • Bluewater Clinical Research Group Inc.

    Sarnia, Ontario, N7T 4X3

  • Diabetes Clinic

    Smiths Falls, Ontario, K7A 4W8

  • Canadian Phase Onward

    Toronto, Ontario, M3J 0K2

  • LMC Clinical Research Inc. (Bayview)

    Toronto, Ontario, M4G 3E8

  • Diabetes Heart Research Centre

    Toronto, Ontario, M6G 1M2

  • Dr. Anil K. Gupta Medicine Professional Corporation

    Toronto, Ontario, M9V 4B4

  • BC Diabetes Office

    Vancouver, British Columbia, V5Y 3W2

  • Dr. M.B. Jones Inc.

    Victoria, British Columbia, V8V 4A1

  • Winnipeg Clinic

    Winnipeg, Manitoba, MB R3C 0N2

Other trials in Canada

Mexico24 sites

  • Centro de Investigacion Medica Aguascalientes

    Aguascalientes, 20116

  • Fundación Cardiovascular de Aguascalientes A.C.

    Aguascalientes, 20230

  • Hospital Cardiologica Aguescalientes

    Aguascalientes, 20230

  • Investigacion En Salud Y Metabolismo S.C / Nutricion Clinica / Unidad de Base de Datos

    Chihuahua City, 31110

  • Centro de Estudios de Investigacion Metabolicos y Cardiovasculares

    Ciudad Madero, Tamaulipas, 89440

  • Instituto de Diabetes, Obesidad y Nutricion

    Cuernavaca, Morelos, 62250

  • Centro Para El Desarrollo de La Medicina Y de Asistencia Medica Especializada S.C.

    Culiacán, Sinaloa, 80230

  • Lahoja. Asociacion Para La Investigacion Y La Farmacovigilancia

    Durango, 34000

  • Diseno y Planeacion en Investigacion Medica

    Guadalajara, Jalisco, 44130

  • Unidad de Investigaci�n Cl�nica Cardiometabolica de Occidente

    Guadalajara, Jalisco, 44150

  • Centro de Investigacion Medica Integral

    Guadalajara, Jalisco, 44160

  • Centro de Investigacion Medica de Occidente, S.C.

    Guadalajara, Jalisco, 44260

  • Universidad de Guadalajara

    Guadalajara, Jalisco, 44340

  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad

    Guadalajara, Jalisco, 4460

  • Private Practice - Dr. Arechavaleta Granell Maria del Rosario

    Guadalajara, Jalisco, 44670

  • Salud Cardiovascular

    Guadalajara, Jalisco, 44860

  • Medical Care and Research SA de CV

    Mérida, Yucatán, 97070

  • Centro Especializado En Diabetes, Obesidad Y Prevencion De Enfermedades Cardiovasculares

    Mexico City, Mexico City, 11650

  • Cardiolink Clin Trials

    Monterrey, Nuevo León, 64060

  • Hospital Universitario "Dr. Jose Eleuterio Gonzalez"

    Monterrey, Nuevo León, 66460

  • Centro de Estudios Clínicos de Querétaro (CECLIQ)

    Querétaro, 76000

  • Unidad Médica para la Salud Integral

    San Nicolás de los Garza, Nuevo León, 66465

  • Centro de Investigacion Cardiovascular y Metabólica

    Tijuana, Estado de Baja California, 22500

  • Hospital Angeles Xalapa

    Xalapa, Veracruz, 91193

Other trials in Mexico

China23 sites

  • Beijing Anzhen Hospital, Capital Medical University

    Beijing, Beijing Municipality, 100029

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100034

  • Beijing Friendship Hospital

    Beijing, Beijing Municipality, 100050

  • China-Japan Union Hospital

    Changchun, Jilin, 130033

  • Hunan Provincial People's Hospital

    Changsha, Hunan, 410005

  • The First Affiliated Hospital, Sun Yat-sen University

    Guangzhou, Guangdong

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150001

  • First Huai'an Hospital Affiliated to Nanjing Medical University

    Huai'an, Jiangsu, 223300

  • Jinan Central Hospital

    Jinan, Shandong, 250013

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, 730000

  • Lanzhou university second hospital

    Lanzhou, Gansu, 730030

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330006

  • Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, 210000

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, 210009

  • The Second Affiliated Hospital of Nanjing Medical University

    Nanjing, Jiangsu, 210011

  • Nanjing First Hospital

    Nanjing, Jiangsu, 210012

  • Jiangxi Pingxiang People's Hospital

    Pingxiang, Jiangxi, 337055

  • The People's Hospital of Liaoning Province

    Shenyang, Liaoning, 110016

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710061

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, 750004

  • Affiliated Hospital of Jiangsu University

    Zhenjiang, Jiangsu, 212000

Other trials in China

Israel23 sites

  • Emek Medical Center

    Afula, Northern District, 1834111

  • Barzilai Medical Center

    Ashkelon, Southern District, 7830604

  • Clalit Health Services - Atlit

    Atlit, Ḥeifā, 30300

  • Soroka Medical Center

    Beersheba, Southern District, 8410101

  • Hillel Yaffe Medical Center

    Hadera, Northern District, 3810101

  • Rambam Health Care Campus

    Haifa, Northern District, 3109601

  • Bnai Zion Medical Center

    Haifa, Ḥeifā, 3339419

  • Linn Medical Center

    Haifa, Ḥeifā, 3515209

  • Edith Wolfson Medical Center

    Holon, Central District, 5810001

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, 9013102

  • Hadassah Medical Center

    Jerusalem, Jerusalem, 9112001

  • Hadassah Mount Scopus Medical Centre

    Jerusalem, Jerusalem, 9124001

  • Clalit Health Services Diabetes and Endocrinology Clinic Jerusalem

    Jerusalem, Jerusalem, 93106

  • Meir Medical Center

    Kfar Saba, Central District, 4428164

  • Galilee Medical Center

    Nahariya, Northern District, 2210001

  • Holy Family Hospital

    Nazareth, Northern District, 16100

  • Rabin Medical Center - Hasharon Campus

    Petah Tikva, Central District, 49202

  • Rabin Medical Center

    Petah Tikva, Central District

  • Sheba Medical Center

    Ramat Gan, Central District, 5262100

  • Kaplan Medical Center

    Rehovot, Central District, 7610001

  • ZIV Medical Center

    Safed, Northern District, 1311001

  • Clalit Health Services - Sakhnin Community Clinic

    Sakhnin, Northern District, 3081000

  • Sourasky Medical Center

    Tel Aviv, Tell Abīb, 6423906

Other trials in Israel

Russia23 sites

  • Arkhangelsk Regional Clinical Hospital

    Arkhangelsk, Arkhangelskaya oblast, 163045

  • First City Clinical Hospital E.E. Volosevich

    Arkhangelsk, Arkhangelskaya oblast, 163045

  • National Medical Research Center for therapy and preventive medicine

    Moscow, Moscow, 101990

  • Endocrinology Research Center of Rosmedtechnologies

    Moscow, Moscow, 117036

  • Pirogov Russian National Research Medical University

    Moscow, Moscow, 117997

  • First Moscow State Medical University I.M. Sechenov

    Moscow, Moscow, 119991

  • Russian Cardiology Research and Production Complex

    Moscow, Moscow, 121552

  • Moscow City Clinical Hospital Number 52

    Moscow, Moscow, 123182

  • M. F. Vladimirskiy Moscow Regional Research Clinical Institute

    Moscow, Moscow, 129110

  • Moscow City Clinical Hospital Number 52

    Moscow, Moscow

  • Novosibirsk State Medical University

    Novosibirsk, Novosibirsk Oblast, 630087

  • Rostov State Medical University

    Rostov-on-Don, Rostov Oblast, 344022

  • Ryazan Regional Clinical Cardiological Dispensary

    Ryazan, Ryazan Oblast, 390026

  • City Mariinskaya Hospital

    Saint Petersburg, Leningradskaya Oblast', 191104

  • S.M. Kirov Military Medical Academy

    Saint Petersburg, Sankt-Peterburg, 194044

  • Saint-Petersburg City Hospital of Saint Elizabeth

    Saint Petersburg, Sankt-Peterburg, 195257

  • Astarta Clinic

    Saint Petersburg, Sankt-Peterburg, 199226

  • Regional Clinical Hospital of the Saratov Region

    Saratov, Saratov Oblast, 410053

  • Advisory Diagnostic Centre

    Syktyvkar, Komi, 167000

  • Tomsk Regional Clinical Hospital

    Tomsk, Tomsk Oblast, 634063

  • Siberian State Medical University

    Tomsk, Tomsk Oblast

  • Research & Practice

    Yaroslavl, Yaroslavl Oblast, 150003

  • Yaroslavl State Med Acad Clinical Hospital

    Yaroslavl, Yaroslavl Oblast, 150010

Other trials in Russia

Ukraine21 sites

  • Regional Communal Non-commercial enterprise "Chernivtsi regional clinical hospital"

    Chernivtsi, Chernivetska Oblast, 58000

  • Dnipropetrovsk City Clinical Hospital No. 9

    Dnipro, Dnipropetrovsk Oblast, 49023

  • Ukrainian State Research Institute Of Medical And Social Problems Of Disability

    Dnipro, Dnipropetrovsk Oblast, 49027

  • City Clinical Hospital No. 2

    Kharkiv, Kharkiv Oblast, 61037

  • L.T. Mala National Institute of Therapy of NAMS of Ukraine

    Kharkiv, Kharkiv Oblast, 61039

  • Municipal Non-Profit Enterprise "City clinical hospital №8" of Kharkiv city council

    Kharkiv, Kharkiv Oblast, 61176

  • Institute of Endocrinology and Metabolism named after Komissarenko

    Kiev, Kyiv Oblast, 04114

  • Medical Center of Limited Liability Company "Medical Center "Consilium Medical"

    Kiev, Kyiv Oblast, 4050

  • Institute of Endocrinology and Metabolism named after Komissarenko

    Kiev, Kyiv Oblast, 4114

  • ARTEM

    Kiev, Kyivska Oblast, 04050

  • Medbud Clinic

    Kyiv, Kyivska Oblast, 3037

  • Medical Center Ok!Clinic+

    Kyiv, 02091

  • Branch "Center of Endocrinological Health" of "Lviv Regional Clinical Diagnostic Center"

    Lviv, Lviv Oblast, 79000

  • Lviv City Clinical Hospital #4

    Lviv, Lviv Oblast, 79011

  • Municipal non-profit enterprise'Odesa Regional Clinical Hospital'of Odesa Regional Council

    Odesa, Odesa Oblast, 65025

  • Municipal non-profit enterprise "Consultative-diagnostic center №20" of Odesa city council

    Odesa, Odesa Oblast, 65114

  • Poltova Oblast Clinical Hospital IM.M.V.Sklifosovskoho

    Poltava, Poltava Oblast, 36011

  • Municipal enterprise "1st City clinical hospital of Poltava City Council", Poltava State Medical University

    Poltava, Poltava Oblast, 36038

  • Municipal Non-Profit Enterprise Of Sumy Regional Council ''Sumy Regional Clinical Hospital''

    Sumy, Sumska Oblast, 40031

  • Vinnytsia Regional Clinical Endocrinology Dispensary

    Vinnytsia, Vinnytsia Oblast, 21010

  • Municipal non-profit enterprise "City Hospital #7" of Zaporizhzhia City Council

    Zaporizhzhya, Zaporizhzhia Oblast, 69118

Other trials in Ukraine

Australia20 sites

  • Nightingale Research

    Adelaide, South Australia, 5000

  • Royal Adelaide Hospital

    Adelaide, South Australia, 5000

  • Box Hill Hospital

    Box Hill, Victoria, 3128

  • Royal Brisbane and Women's Hospital

    Brisbane, Queensland, 4029

  • Core Research Group

    Brisbane, Queensland, 4064

  • Mater Misericordiae Limited

    Brisbane, Queensland, 4101

  • Victorian Heart Hospital

    Clayton, Victoria, 3168

  • School of Medicine, Fremantle Hospital

    Fremantle, Western Australia, 6160

  • Barwon Health

    Geelong, Victoria, 3220

  • Austin Health - Repatriation Hospital

    Heidelberg West, Victoria, 3084

  • Advara HeartCare Joondalup

    Joondalup, Western Australia, 6027

  • Launceston General Hospital

    Launceston, Tasmania, 7250

  • The AIM Centre / Hunter Diabetes Centre

    Merewether, New South Wales, 2291

  • GenesisCare - Murdoch - Murdoch Drive

    Murdoch, Western Australia, 6150

  • Southern Adelaide Diabetes & Endocrine Services

    Oaklands Park, South Australia, 5046

  • Nepean Hospital

    Penrith, New South Wales, 2747

  • Gold Coast University Hospital

    Southport, Queensland, 4215

  • University of Sydney - Charles Perkins Centre

    Sydney, New South Wales, 2006

  • The Townsville Hospital

    Townsville, Queensland, 4814

  • Illawarra Shoalhaven Local Health District

    Wollongong, New South Wales, 2500

Other trials in Australia

Italy20 sites

  • A.O.U.C. Policlinico di Bari

    Bari, Apulia, 70124

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

    Bergamo, Lombardy, 24127

  • IRCCS - AOU di Bologna

    Bologna, 40138

  • Azienda Ospedaliera Garibaldi

    Catania, 95124

  • Azienda Ospedaliera Mater Domini

    Catanzaro, 88100

  • Ospedale Maggiore Pronto Soccorso

    Chieri, Torino, 10023

  • Università degli Studi Gabriele D' Annunzio

    Chieti, 66100

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, 50134

  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, 20122

  • Centro Cardiologico Monzino

    Milan, 20138

  • Universita degli Studi della Campania Luigi Vanvitelli

    Naples, Campania, 80138

  • Ospedale san Giovanni di Dio-Diabetologia

    Olbia, Sardinia, 7026

  • A.O.U. Policlinico Paolo Giaccone

    Palermo, Sicily, 90129

  • Azienda Ospedaliero Universitaria di Parma

    Parma, 43126

  • Fondazione Salvatore Maugeri Clinica del lavoro

    Pavia, 27100

  • Azienda Ospedaliera Universitaria Pisana

    Pisa, Tuscany, 56124

  • Fondazione Policlinico Tor Vergata

    Rome, Lazio, 133

  • Fondazione Policlinico Universitario Agostino Gemelli

    Rome, Lazio, 168

  • Ospedale San Giovanni Calibita Fatebenefratelli

    Rome, Lazio, 186

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento

    Verona, Veneto, 37126

Other trials in Italy

Romania20 sites

  • Private Practice - Dr. Diana Barbonta

    Alba Iulia, Alba, 510134

  • CMI Dr.Pletea Noemi SRL

    Bacau, 600154

  • SC Minimed SRL

    Bacau, 600238

  • CMI DNBM Dr. Pop Lavinia

    Baia Mare, Maramureş, 430222

  • C.M.D.T.A. Neomed

    Brasov, Brașov County, 500283

  • Nicodiab

    Bucharest, Bucharest, 10507

  • Geea Medical Easy Diet

    Bucharest, Bucharest, 10627

  • Centrul Medical NutriLife

    Bucharest, Bucharest, 13764

  • The National Institute of Diabetes, Nutrition and Metabolic Diseases "Prof. Dr. N. Paulescu"

    Bucharest, Bucharest, 20475

  • Top Diabet SRL

    Craiova, Dolj, 200678

  • Diamed Obesity

    Galați, 800291

  • Olimpia Med

    Iași, 400002

  • Centrul Medical Consultmed

    Iași, 700514

  • Gama Diamed

    Mangalia, Constanța County, 905500

  • Diabdana

    Oradea, Bihor County, 410147

  • Centrul Medical Grandmed

    Oradea, Bihor County, 410159

  • Diabmed Dr. Popescu Alexandrina

    Ploieşti, Prahova, 100163

  • Dianutrilife Medica

    Ploieşti, Prahova, 100561

  • SC Dentosim Queen SRL - Centrul Medical Diamed

    Târgu Mureş, Mureș County, 540098

  • Centru Medical Dr. Negrisanu

    Timișoara, Timiș County, 300456

Other trials in Romania

Spain20 sites

  • CHUAC-Complejo Hospitalario Universitario A Coruña

    A Coruña, A Coruña [La Coruña], 15006

  • Hospital Universitario Príncipe de Asturias

    Alcalá de Henares, Madrid, Comunidad de, 28805

  • Centro Periférico de Especialidades Bola Azul

    Almería, Almería, 4009

  • Hospital Universitario de La Ribera

    Alzira, València, 46600

  • Complejo Hospitalario Universitario de Ferrol (CHUF)- Hospital Naval

    Ferrol, A Coruña [La Coruña], 15405

  • Hospital Unviersitario Virgen Nieves

    Granada, 18012

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Comunidad de, 28034

  • Hospital Universitario La Paz

    Madrid, 28046

  • Hospital Universitario Virgen de la Victoria

    Málaga, Andalusia, 29010

  • Hospital Universitario Central de Asturias

    Oviedo, Asturias, Principado de, 33011

  • Hospital Universitario Quironsalud Madrid

    Pozuelo de Alarcón, Madrid, 28223

  • Hospital Virgen del Camino

    Sanlúcar de Barrameda, Cádiz, 11540

  • CHUS - Hospital Clinico Universitario

    Santiago de Compostela, A Coruña [La Coruña], 15706

  • Hospital Quiron Infanta Luisa

    Seville, Andalusia, 41010

  • Clínica nuevas Tecnologías en Diabetes y Endocrinología (NTDE)

    Seville, 41003

  • Hospital Universitario Virgen Macarena

    Seville, 41009

  • Hospital General Universitario de Valencia

    Valencia, Valenciana, Comunitat, 46014

  • Hospital Universitari i Politecnic La Fe

    Valencia, 46026

  • Hospital Clínico Universitario de Valladolid

    Valladolid, Castille and León, 47003

  • Hospital Virgen de las Montañas

    Villamartín, Cádiz, 11650

Other trials in Spain

Poland19 sites

  • Legeartis - Poradnie Specjalistyczne

    Bialystok, Podlaskie Voivodeship, 15-404

  • Niepubliczny Specjalistyczny Zaklad Opieki Zdrowotnej Osrodek Diabetologiczny Popula Spolka Cywilna

    Bialystok, Podlaskie Voivodeship, 15445

  • Centrum Badan Klinicznych PI-House sp. z o.o.

    Gdansk, Pomeranian Voivodeship, 80-546

  • NZOZ Salvia CM

    Katowice, Silesian Voivodeship, 40-772

  • Medyczne Centrum Diabetologiczno Endokrynologiczno Metaboliczne DIAB-ENDO-MET

    Krakow, Lesser Poland Voivodeship, 31-261

  • Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna

    Lodz, Łódź Voivodeship, 90338

  • CenterMed Lublin NZOZ

    Lublin, Lublin Voivodeship, 20-044

  • Gabinety TERPA

    Lublin, Lublin Voivodeship, 20-333

  • NZOZ Medica

    Lublin, Lublin Voivodeship, 20-538

  • OMEDICA Medical Center

    Poznan, Greater Poland Voivodeship, 60-111

  • Gaja Poradnie Lekarskie Maciej Wiza

    Poznan, Greater Poland Voivodeship, 61-251

  • Private Practice - Dr. Ewa Krzyzagorska

    Poznan, Greater Poland Voivodeship, 61-655

  • NZOZ Przychodnia Specjalistyczna Andrzej Wittek, Henryk Rudzki

    Ruda Śląska, Silesian Voivodeship, 41-709

  • Private Practice - Dr. Robert Witek

    Tarnów, Lesser Poland Voivodeship, 33-100

  • Centrum Medyczne AMED

    Warsaw, Masovian Voivodeship, 00-215

  • Instytut Diabetologii

    Warsaw, Masovian Voivodeship, 02-117

  • ETG NETWORK Sp. z o.o.

    Warsaw, Masovian Voivodeship, 02-677

  • NZOZ Regionalna Poradnia Diabetologiczna

    Wroclaw, Lower Silesian Voivodeship, 50-127

  • Wojewódzki Zespól Specjalistycznej Opieki Zdrowotnej

    Wroclaw, Lower Silesian Voivodeship, 50-403

Other trials in Poland

Turkey (Türkiye)19 sites

  • Akdeniz Universitesi Hastanesi

    Antalya, 7070

  • Adnan Menderes University Medical Faculty

    Aydin, 9100

  • Dokuz Eylül Üniversitesi

    Balçova, İzmir, 35340

  • Ege Universitesi Hastanesi

    Bornova, İzmir, 35100

  • Pamukkale University Medical Faculty, Fahri Goksin Oncology Centre

    Denizli

  • Atatürk Üniversitesi

    Erzurum, 25070

  • Eskisehir Osmangazi University

    Eskişehir, Eskişehir, 26040

  • Gaziantep Üniversitesi Gaziantep Onkoloji Hastanesi

    Gaziantep, 27000

  • Koç Üniversitesi Hastanesi

    Istanbul, 34010

  • Dr. Sadi Konuk Egitim ve Arastirma Hastanesi

    Istanbul, 34147

  • Acibadem Universitesi Atakent Hastanesi

    Istanbul, 34303

  • Göztepe Eitim Ve Aratrma Hastanesi

    Istanbul, 34722

  • Fatih Sultan Mehmet Training and Research Hospital

    Istanbul, 34752

  • Erciyes University Medical Faculty

    Kayseri, 38030

  • Kocaeli Üniversitesi

    Kocaeli, 41380

  • İnönü Üniversitesi Turgut Özal Tıp Merkezi

    Malatya, 44280

  • Dicle Üniversitesi

    Sur, Diyarbakır, 21200

  • Mersin University Medical Faculty

    Yenişehir, Mersin, 33110

  • Baskent University Dr. Turgut Noyan Research and Training Center

    Yüreğir, Adana, 01250

Other trials in Turkey (Türkiye)

Netherlands18 sites

  • Jeroen Bosch ziekenhuis

    's-Hertogenbosch, North Brabant, 5223 GZ

  • EB Utrecht

    Almere Stad, Flevoland, 1311RL

  • Ziekenhuis Amstelland

    Amstelveen, North Holland, 1186 AM

  • Amsterdam UMC, locatie VUmc

    Amsterdam, North Holland, 1081 HV

  • Amsterdam UMC, locatie AMC

    Amsterdam, North Holland, 1105 AZ

  • Ziekenhuis Rijnstate

    Arnhem, Gelderland, 6815 AD

  • Reinier de Graaf Ziekenhuis, locatie Delft

    Delft, South Holland, 2625 AD

  • Het Van Weel-Bethesda Ziekenhuis - Ziekenhuis Dirksland

    Dirksland, South Holland, 3247 BW

  • Slingeland Ziekenhuis

    Doetinchem, Gelderland, 7009 BL

  • Ziekenhuis Gelderse Vallei

    Ede, Gelderland, 6716 RP

  • Spaarne Gasthuis, Haarlem Zuid

    Haarlem, North Holland, 2035 RC

  • Saxenburgh Medisch Centrum

    Hardenberg, Overijssel, 7772 SE

  • Ziekenhuis Bethesda

    Hoogeveen, Drenthe, 7909 AA

  • Radboudumc

    Nijmegen, Gelderland, 6525 GA

  • Canisius-Wilhelmina Ziekenhuis

    Nijmegen, Gelderland, 6532 SZ

  • Franciscus Gasthuis & Vlietland, Locatie Gasthuis

    Rotterdam, South Holland, 3045 PM

  • Diakonessenhuis, locatie Utrecht

    Utrecht, 3582 KE

  • Universitair Medisch Centrum Utrecht

    Utrecht, 3584 CX

Other trials in Netherlands

Hungary17 sites

  • DRC Gyógyszervizsgáló Központ

    Balatonfüred, Veszprém megye, 8230

  • Szent Margit Rendelőintézet Nonprofit Kft

    Budapest, 1032

  • ClinDiab Kft.

    Budapest, 1089

  • Szent János Kórház

    Budapest, 1125

  • Magyar Honvedseg Egeszsegugyi Kozpont

    Budapest, 1134

  • Strazsahegy Medicina Bt.

    Budapest, H1171

  • Debreceni Egyetem Kenézy Gyula Egyetemi Kórház

    Debrecen, Hajdú-Bihar, 4031

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, 4032

  • Markhot Ferenc Oktatókórház

    Eger, Heves County, 3300

  • Pharma 4 Trial

    Gyöngyös, Heves County, 3200

  • Studium Egeszseghaz Kft

    Kalocsa, Bács-Kiskun county, 6300

  • Selye János Kórház

    Komárom, Komárom-Esztergom, 2900

  • Kanizsai Dorottya Korhaz

    Nagykanizsa, Zala County, 8800

  • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ

    Szeged, Csongrád megye, 6725

  • Fejér Megyei Szent György Egyetemi Oktató Kórház

    Székesfehérvár, Fejér, 8000

  • CLINFAN Szolgáltató Kft

    Szekszárd, Tolna County, 7100

  • Zala Megyei Szent Rafael Kórház

    Zalaegerszeg, Zala County, 8900

Other trials in Hungary

Brazil15 sites

  • Instituto de Pesquisa clinica de Campinas

    Campinas, São Paulo, 13060-080

  • Loema Instituto de Pesquisa Clinica

    Campinas, São Paulo, 13092-133

  • Quanta Diagnóstico e Terapia

    Curitiba, Paraná, 80045170

  • Private Practice - Dr.Miguel N. Hissa

    Fortaleza, Ceará, 60430-350

  • CECIP - Centro de Estudos do Interior Paulista

    Jaú, São Paulo, 17201130

  • Núcleo de Pesquisa Clínica do Rio Grande do Sul

    Porto Alegre, Rio Grande do Sul, 90430-001

  • IBPClin - Instituto Brasil de Pesquisa Clínica

    Rio de Janeiro, 22241-180

  • Faculdade de Medicina do ABC

    Santo André, São Paulo, 09060-870

  • ISPEM - Instituto São José dos Campos em Pesquisas Médicas

    São José dos Campos, São Paulo, 12243-280

  • Instituto de Pesquisa Clinica

    São Paulo, São Paulo, 01223-001

  • CPCLIN

    São Paulo, São Paulo, 01228-200

  • CPQuali Pesquisa Clínica

    São Paulo, 01228-000

  • Hospital das Clinicas FMUSP

    São Paulo, 04266-010

  • Hospital das Clinicas FMUSP

    São Paulo, 05403-000

  • CEDOES

    Vitória, Espírito Santo, 29055450

Other trials in Brazil

Belgium14 sites

  • AZORG Campus Aalst-Moorselbaan

    Aalst, Oost-Vlaanderen, 9300

  • Imelda General Hospital

    Bonheiden, Antwerpen, 2820

  • Algemeen Ziekenhuis klina

    Brasschaat, Antwerpen, 2930

  • AZ Sint-Jan Brugge-Oostende AV

    Bruges, West-Vlaanderen, 8000

  • Université Libre de Bruxelles - Hôpital Erasme

    Brussels, Bruxelles-Capitale, Région de, 1070

  • UZ Brussel

    Brussels, Bruxelles-Capitale, Région de, 1090

  • Antwerp University Hospital

    Edegem, Antwerpen, 2650

  • AZ Groeninge Campus Kennedylaan

    Kortrijk, West-Vlaanderen, 8500

  • UZ Leuven

    Leuven, Vlaams-Brabant, 3000

  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman

    Liège, 4000

  • ZAS Jan Palfijn

    Merksem, Flanders, 2170

  • Az Damiaan vzw

    Ostend, West-Vlaanderen, 8400

  • AZ Delta vzw

    Roeselare, West-Vlaanderen, 8800

  • AZ Nikolaas

    Sint-Niklaas, Oost-Vlaanderen, B-9100

Other trials in Belgium

India14 sites

  • Gujarat Endocrin Pvt Ltd

    Ahmedabad, Gujarat, 380052

  • Marengo CIMS Hospital

    Ahmedabad, Gujarat, 380060

  • Bangalore Diabetes Centre

    Bangalore, Karnataka, 560043

  • Madras Diabetes Research Foundation

    Chennai, Tamil Nadu, 600086

  • Care Hospitals Hyderabad- Banjara Hills

    Hyderabad, Telangana, 500034

  • CARE CHL-Hospitals

    Indore, Madhya Pradesh, 452008

  • Apollo Multispeciality Hospitals limited

    Kolkata, West Bengal, 700054

  • Topiwala National Medical College & B. Y. L. Nair Charitable Hospital

    Mumbai, Maharashtra, 400008

  • King Edward Memorial Hospital & Seth Gordhandas Sunderdas Medical College

    Mumbai, Maharashtra, 400012

  • Kingsway Hospitals (Best Multispeciality Hospital in Nagpur)

    Nagpur, Maharashtra, 440001

  • G.B. Pant Institute of Postgraduate Medical Education & Research

    New Delhi, National Capital Territory of Delhi, 110002

  • All India Institute of Medical Sciences

    New Delhi, National Capital Territory of Delhi, 110029

  • Sir Ganga Ram Hospital

    New Delhi, National Capital Territory of Delhi, 110060

  • Batra Hospital and Medical Research Centre

    New Delhi, National Capital Territory of Delhi, 110062

Other trials in India

United Kingdom12 sites

  • Aberdeen Royal Infirmary

    Aberdeen, Aberdeen City, AB25 2ZN

  • Southmead Hospital

    Bristol, Bristol, City of, BS10 5NB

  • Ninewells Hospital and Medical School

    Dundee, Angus, DD1 9SY

  • Staploe Medical Centre

    Ely, Cambridgeshire, CB7 5JD

  • Glasgow Royal Infirmary

    Glasgow, Glasgow City, G4 0SF

  • Hull Royal Infirmary

    Hull, Kingston Upon Hull, HU3 2JZ

  • Ipswich Hospital

    Ipswich, Suffolk, IP4 5PD

  • Leicester General Hospital

    Leicester, Leicestershire, LE5 4PW

  • University Hospital Aintree

    Liverpool, L9 7AL

  • Knowle House Surgery

    Plymouth, Devon, PL5 3JB

  • Morriston Hospital

    Swansea, Swansea [Abertawe Gb-ata], SA6 6SG

  • The Royal Cornwall Hospital

    Truro, England, TR1 3LJ

Other trials in United Kingdom

France11 sites

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, Île-de-France Region, 91106

  • Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand

    Dijon, Côte-d'Or, 21000

  • Hôtel-Dieu du Creusot - site Harfleur

    Le Creusot, Bourgogne-Franche-Comté, 71200

  • Assistance Publique Hôpitaux de Paris - Groupe Hospitalier 10e - Hôpital Lariboisière

    Paris, 75010

  • Hôpital Bichat - Claude-Bernard

    Paris, 75018

  • Groupe hospitalier Paris saint Joseph

    Paris, Île-de-France Region, 75014

  • CHU Bordeaux Haut-Leveque

    Pessac, Aquitaine, 33600

  • Hôpital Nord Guillaume-et-René-Laennec / CHU de Nantes

    Saint-Herblain, Loire-Atlantique, 44800

  • CHU Rangueil

    Toulouse, Haute-Garonne, 31059

  • Centre Hospitalier Régional Universitaire de Nancy - Hôpitaux de Brabois

    Vandœuvre-lès-Nancy, Lorraine, 54511

  • Groupe Hospitalier Mutualiste Les Portes du Sud

    Vénissieux, Auvergne-Rhône-Alpes, 69200

Other trials in France

Czechia10 sites

  • Diacentrum Brandys n.L. s.r.o.

    Brandýs nad Labem, Praha-východ, 25001

  • MUDr. Alena Vachova

    České Budějovice, South Bohemian Region, 37011

  • MUDr. Tomas Edelsberger

    Krnov, Moravian-Silesian Region, 79401

  • Interni a diabetologicka ordinace, s.r.o.

    Náchod, Náchod, 547 01

  • Diabet2 s.r.o., diabetologicka a interni ambulance

    Prague, Praha 1, 11000

  • ResTrial s.r.o.

    Prague, Praha 8, 18100

  • Vseobecna fakultni nemocnice v Praze

    Prague, 12808

  • MUDr. Michala Pelikanova s.r.o.

    Prague, 140 00

  • Milan Kvapil s.r.o., Diabetologicka ambulance

    Prague, 14900

  • MUDr. Barbora Diepoltova

    Praha 9 - Klanovice, Praha 9, 190 14

Other trials in Czechia

Greece10 sites

  • Athens Euroclinic

    Athens, Attikí (Region), 115 21

  • General Hospital of Athens "G. Gennimatas"

    Athens, Attikí, 11527

  • Attikon General University Hospital

    Chaïdári, Attikí, 12462

  • University General Hospital of Larissa

    Larissa, Thessalía, 41110

  • Iatriko Paleou Falirou Medical Center

    Palaió Fáliro, Attikí (Region), 17562

  • Thermi Clinic

    Thermi, Thessaloniki, Thessaloníki, 570 01

  • Ippokrateio General Hospital of Thessaloniki

    Thessaloniki, Kentrikí Makedonía, 54642

  • AHEPA University General Hospital of Thessaloniki

    Thessaloniki, Thessaloníki, 546 36

  • Euromedica General Clinic of Thessaloniki

    Thessaloniki, Thessaloníki, 546 45

  • Papageorgiou General Hospital of Thessaloniki

    Thessaloniki, Thessaloníki, 564 03

Other trials in Greece

South Korea10 sites

  • Keimyung University Dongsan Hospital

    Daegu, Taegu-Kwangyǒkshi, 42601

  • Korea University Anam Hospital

    Seoul, Seoul-teukbyeolsi [Seoul], 2841

  • Seoul National University Hospital

    Seoul, Seoul-teukbyeolsi [Seoul], 3080

  • Severance Hospital, Yonsei University Health System

    Seoul, Seoul-teukbyeolsi [Seoul], 3722

  • Kyung Hee University Hospital at Gangdong

    Seoul, Seoul-teukbyeolsi [Seoul], 5278

  • Asan Medical Center

    Seoul, Seoul-teukbyeolsi [Seoul], 5505

  • The Catholic Univ. of Korea Seoul St. Mary's Hospital

    Seoul, Seoul-teukbyeolsi [Seoul], 6591

  • Hallym University Kangnam Sacred Heart Hospital

    Seoul, Seoul-teukbyeolsi [Seoul], 7441

  • Ulsan University Hospital

    Ulsan, Ulsan-Kwangyǒkshi, 44033

  • Yonsei University-Wonju Severance Christian Hospital

    Wŏnju, Kang-won-do, 26426

Other trials in South Korea

Japan9 sites

  • The Institute of Medical Science, Asahi Life Foundation

    Chuo-ku, Tokyo, 103-0002

  • Tokyo-Eki Center-building Clinic

    Chuo-ku, Tokyo, 103-0027

  • Fukuwa Clinic

    Chuo-ku, Tokyo, 104-0031

  • Jinnouchi Hospital

    Kumamoto, 862-0976

  • Medical Corporation Sato Medical clinic

    Ootaku, Tokyo, 143-0015

  • AMC Nishiumeda Clinic

    Osaka, 530-0001

  • Sakurabashi Watanabe Advanced Healthcare Hospital

    Osaka, 530-0005

  • Takatsuki Red Cross Hospital

    Takatsuki, Osaka, 569-1045

  • Uji-Tokushukai Medical Center

    Uji, Kyoto, 611-0041

Other trials in Japan

Slovakia9 sites

  • Diacrin s.r.o.

    Bratislava, Bratislava Region, 831 01

  • IN-DIA

    Lučenec, Banská Bystrica Region, 984 01

  • Sin Azucar

    Malacky, Bratislava Region, 901 01

  • Funkystuff

    Nové Zámky, Nitra Region, 940 01

  • Diabetol

    Prešov, Presov, 080 01

  • DIA-MED CENTRUM s.r.o.

    Púchov, Trenčín Region, 020 01

  • DIAB sro

    Rožňava, Košice Region, 048 01

  • MED-DIA s.r.o

    Sabinov, Presov, 8301

  • Diabetes Centrum

    Trenčín, Trenčín Region, 911 01

Other trials in Slovakia

Taiwan9 sites

  • Changhua Christian Hospital

    Changhua County, Changhua, 50006

  • Mackay Memorial Hospital-Hsinchu

    Hsinchu, Hsinchu, 300

  • Hualien Tzu Chi Medical Center

    Hualien City, Hualien, 970

  • Chang Gung Memorial Hospital at Kaohsiung

    Kaohsiung Niao Sung Dist, Kaohsiung, 83301

  • Taichung Veterans General Hospital

    Taichung, 407

  • Chi Mei Medical Center

    Tainan, Tainan, 71004

  • National Cheng-Kung Uni. Hosp.

    Tainan, 704

  • Taipei Veterans General Hospital

    Taipei, 11217

  • Chang Gung Medical Foundation-Linkou Branch

    Taoyuan, 333

Other trials in Taiwan

Austria6 sites

  • Medizinische Universität Graz

    Graz, Styria, 8036

  • Uniklinikum Salzburg

    Salzburg, 5020

  • Klinik Landstraße

    Vienna, 1030

  • Zentrum für klinische Studien Dr Hanusch Gmbh

    Vienna, 1060

  • Universitaetsklinikum Allgemeines Krankenhaus Wien

    Vienna, 1090

  • Klinik Hietzing

    Vienna, 1130

Other trials in Austria

Sweden6 sites

  • ProbarE

    Lund, Skåne Län [se-12], 222 22

  • Sahlgrenska Universitetssjukhuset Mölndal

    Mölndal, Västra Götalands Län [se-14], 431 80

  • Universitetssjukhuset Örebro

    Örebro, Örebro Län [se-18], 701 85

  • Östersunds Sjukhus

    Östersund, Jämtlands Län [se-23], 831 31

  • Dalecarlia Clinical Research Center

    Rättvik, Dalarnas Län [se-20], 795 30

  • Citydiabetes

    Stockholm, Stockholms Län [se-01], 112 21

Other trials in Sweden

Puerto Rico5 sites

  • Advanced Clinical Research, LLC

    Bayamón, 00959

  • Manati Center for Clinical Research

    Manati, 00674

  • Research and Cardiovascular Corp.

    Ponce, 00717

  • GCM Medical Group, PSC - Hato Rey Site

    San Juan, 00917

  • San Juan City Hospital

    San Juan, 00935

Other trials in Puerto Rico

About this study

Official title: The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)

The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.

Being tested
Tirzepatide, Dulaglutide
Keywords
Diabetes Mellitus, Diabetes Mellitus, Type 2, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases, Hypoglycemic Agents, Physiological Effects of Drugs, Tirzepatide, Incretins, Glucagon-Like Peptide 1, Gastric Inhibitory Polypeptide, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists
Medical subject headings
Diabetes Mellitus, Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Diseases, Endocrine System Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TirzepatideDrug

    Also called LY3298176

    Administered SC

  • DulaglutideDrug

    Also called LY2189265

    Administered SC

Study groups in NCT04255433
Study groupRoleWhat they receive
Tirzepatide - Maximum Tolerated Dose (MTD)ExperimentalParticipants received a starting dose of 2.5 milligrams (mg) tirzepatide administered as subcutaneous (SC) injection once weekly (QW) and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW) for up to 5 years.
Receives: Drug: Tirzepatide
1.5 mg DulaglutideExperimentalParticipants received 1.5 mg dulaglutide administered as SC injection QW for up to 5 years.
Receives: Drug: Dulaglutide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke]

    Number of participants with first occurrence of Clinical Endpoint Committee (CEC), a composite endpoint i.e., from time of randomization to first occurrence of cardiovascular (CV) death, myocardial infarction and stroke combined data was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

Secondary outcomes (13)

  1. Number of Participants From Randomization to Time to Occurrence of All-Cause Death

    The number of participants from randomization to time to occurrence of Clinical Endpoint Committee (CEC) confirmed all-cause death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of all-cause death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  2. Number of Participants From Randomization to Time of Occurrence of CV Death

    Number of participants from time of randomization to time to occurrence of CEC confirmed CV death was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of CV death during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  3. Number of Participants From Randomization to Time to First Occurrence of Myocardial Infarction (MI)

    The number of participants from randomization to first occurrence of CEC confirmed MI was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal MI during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  4. Number of Participants From Randomization toTime to First Occurrence of Stroke

    The number of participants from randomization to first occurrence of CEC confirmed stroke was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of nonfatal stroke during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  5. Number of Participants From Randomization to Time to First Occurrence of the Expanded Composite of CV Death, MI, Stroke or Coronary Revascularization (MACE-4)

    The number of participants from randomization to first occurrence of MACE-4 was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  6. Number of Participants From Randomization to Time to First Occurrence of CV Deaths or Heart Failure Events Requiring Hospitalization and/or Urgent Heart Failure Visits

    The number of participants from randomization to first occurrence of Clinical Endpoint Committee (CEC) confirmed heart failure requiring hospitalisation or urgent heart failure was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of any of these events during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  7. Number of Participants From Randomization to Time to First Occurrence of Revascularization

    The number of participants from randomization to first occurrence of coronary revascularization was reported. Time to event was defined as the number of days from the date of randomization to the first occurrence of revascularization during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  8. Number of Participants From Randomization to Time to First Occurrence of New or Worsening Nephropathy

    New or worsening nephropathy (Composite Endpoint 1) was defined as the first occurrence of any of the following events:

    persistent macroalbuminuria (urine albumin-to-creatinine ratio >300 mg/g), persistent doubling of serum creatinine with eGFR <45 mL/min/1.73 m², onset of end-stage renal disease (including initiation of chronic dialysis or kidney transplantation), or death due to renal disease.

    Time to event was defined as the number of days from the date of randomization to the first occurrence any of these events. during the study follow-up period. Participants without an event were censored at their last known contact or end of follow-up.

    Measured: From randomization (week 0) up to week 259

  9. Change From Baseline to 36 Months in Estimated Glomerular Filtration Rate (eGFR) in Patients With High or Very-high Risk Chronic Kidney Disease (CKD)

    Change from baseline in eGFR calculated as difference between value at 36 months and baseline value. Participants included in this analysis were classified as having high or very high risk of chronic kidney disease at baseline based on their kidney function (eGFR) and urine albumin-to-creatinine ratio (UACR). High risk included participants with eGFR 45 to less than 60 milliliters/minutes/1.73 square metres (mL/min/1.73 m²) and UACR greater than 30 mg/g, or eGFR 60 mL/min/1.73 m² or higher with UACR greater than 300 mg/g. Very high risk included participants with eGFR less than 45 mL/min/1.73 m² or severely increased UACR (greater than 300 mg/g). These criteria are associated with an increased risk of worsening kidney function. Least squares (LS) mean was calculated using analysis of covariance (ANCOVA) model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline sodium-glucose cotransporter-2 (SGLT-2) Use Flag.

    Measured: Baseline, 36 Months

  10. Change From Baseline to 36 Months in Hemoglobin A1c (HbA1c)

    HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Change in HbA1c from baseline up to 36 months during in-trial period were reported. In-trial observation period was defined as the period from date of randomization to the first of (both inclusive): date of follow-up visit, date when participant withdrew consent, date of last contact with participant (for participant lost to follow-up), and date of death.

    LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

    Measured: Baseline, 36 Months

  11. Percent Change From Baseline to 36 Months in Body Weight

    LS mean was calculated using ANCOVA model for endpoint measures: Variable = Baseline + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares)

    Measured: Baseline, 36 Months

  12. Percent Change From Baseline to 36 Months in Urinary Albumin to Creatinine Ratio (UACR)

    Urine samples were collected for the analysis of UACR. UACR (gram per kilograms [g/kg]) was calculated as urine albumin (gram per liter [g/L])/urine creatinine (kg/L). Percent change from baseline at 36 months was calculated as: [(UACR at 36 months - baseline UACR) / baseline UACR] × 100.

    LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag (Type III sum of squares).

    Measured: Baseline, 36 Months

  13. Percent Change From Baseline to 24 Months in Blood Lipids (Total Cholesterol (TC), Low-Density Lipoprotein Cholesterol (LDL-C), High-Density Lipoprotein Cholesterol (HDL-C), and Triglycerides (TG))

    Blood samples of participants who had fasted for 12 to 14 hours were collected for lipid profile (TC, LDL-C, HDL-C, TG) assessment. The lipid profile asesses the risk of heart disease. Percent change from baseline = 100*(post-baseline assessment - baseline assessment)/baseline assessment.

    LS mean was calculated using ANCOVA model for endpoint measures: log(Actual Measurement/Baseline) = log(Baseline) + Treatment + Analysis Country + Baseline SGLT-2i Use Flag.

    Measured: Baseline, 24 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 Feb 2020
  2. Study start29 May 2020
  3. Primary completion12 Jun 2025
  4. Study completion12 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
13,299 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04255433
Sponsor's protocol ID
17073
Other IDs
I8F-MC-GPGN, 2019-002735-28, 2023-507846-96-00, 2023, 2019
Acronym
SURPASS-CVOT
Status last verified
Jun 2026
First submitted
3 Feb 2020
Last updated
8 Jul 2026
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Publications

  • Nissen SE, Wolski K, D'Alessio D, Weerakkody G, Kiljanski J, Wiese RJ, Pavo I, Cariou B, Nicholls SJ. Cardiorenal Outcomes With Tirzepatide Compared With Dulaglutide in Patients With Diabetes and Cardiovascular Disease: A Post Hoc Analysis of the SURPASS-CVOT Randomized Clinical Trial. JAMA Cardiol. 2026 Jun 1;11(6):544-552. doi: 10.1001/jamacardio.2026.0767.

    PubMed 41903177

  • Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji L, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420. doi: 10.1056/NEJMoa2505928.

    PubMed 41406444

  • Khawaji A, A Jaly A, A Bakri H, Ravi R, Hattan A, Khawaji A, Najmi W. Weight Loss Efficacy of Tirzepatide Compared to Placebo or GLP-1 Receptor Agonists in Adults With Obesity or Overweight: A Meta-Analysis of Randomized Controlled Trials With >/= 20 Weeks Treatment Duration. J Obes. 2025 Jul 24;2025:3442754. doi: 10.1155/jobe/3442754. eCollection 2025.

    PubMed 40746703

  • Kaneko S. Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes. touchREV Endocrinol. 2022 Jun;18(1):10-19. doi: 10.17925/EE.2022.18.1.10. Epub 2022 Jun 16.

    PubMed 35949358

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Tirzepatide and Dulaglutide in people with Type 2 Diabetes Mellitus, run by Eli Lilly and Company at 635 sites in 31 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 34 inclusion and 28 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 635 sites in United States, Germany, Argentina, Canada, Mexico and 26 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 8 Jul 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of Participants From Randomization to First Occurrence of Death From MACE-3 [Composite Endpoint of Major Adverse Cardiovascular Events Death From Cardiovascular Causes, Myocardial Infarction (MI) or Stroke] (time frame: From randomization (week 0) up to week 259). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04255433, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in